Operator: Greetings, and welcome to the Kamada Fourth Quarter and Full Year 2024 Earnings Conference Call. At this time all ...

Record Year with Total 2024 Revenues of $161.0 Million, Representing a 13% Increase over Fiscal Year 2023 and Adjusted EBITDA ...

Our two main growth catalysts in 2024 were KEDRAB and CYTOGAM, resulting from increased demand in the U.S. market. We also experienced a meaningful increase in GLASSIA sales in multiple ...

Kamada Ltd (KMDA) reports a 13% revenue increase and unveils plans for biosimilar launches and plasma center expansions.

Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung ...

Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung ...

The Company will withhold tax on the dividend in accordance with Israeli tax law. The Company applied for a ruling from the Israel Tax Authority in connection with tax withholding to non-Israeli ...

The increase in revenues was primarily attributable to KEDRAB and CYTOGAM growth year-over-year. Gross profit and gross margins were $70.0million and 43%, respectively, in the year ended December ...